A U.S. health panel says it's time to resume use of Johnson & Johnson's COVID-19 vaccine, despite a very rare risk of blood clots.
A U.S. health panel says it's time to resume use of Johnson & Johnson's COVID-19 vaccine, despite a very rare risk of blood clots.
World Projected to Spend $157 Billion
on COVID-19 Vaccines by 2025.
On Thursday, IQVIA Holdings Inc released a..
The key facts behind the day's headlines on April 30 as the Health Secretary Matt Hancock encouraged everyone invited for a..